Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
摘要：
Several studies have established a link between aberrant PI(3)K-Akt-mTOR- and Ras-Raf-MEK-Erk1/2 signaling and neuroendocrine tumor disease. In this study, we comparatively investigate the antitumor potential of novel small-molecule inhibitors targeting mTOR (RAD001), mTOR/PI(3)K (NVP-BEZ235) and Raf (Raf265) on human NET cell lines of heterogeneous origin. All inhibitors induced potent antitumor effects which involved the induction of apoptosis and G0/G1 arrest. However, the dual mTOR/PI(3)K inhibitor NVP-BEZ235 was more efficient compared to the single mTOR inhibitor RAD001. Consistently, NVP-BEZ235 prevented the negative feedback activation of Akt as observed after treatment with RAD001. Raf265 inhibited Erk1/2 phosphorylation but strongly induced Akt phosphorylation and VEGF secretion, suggesting the existence of a compensatory feedback loop on PI3K-Akt signaling. Finally, combined treatment with RAD001 or NVP-BEZ235 and Raf265 was more efficient than single treatment with either kinase inhibitor. Together, our data provide a rationale for dual targeting of PI(3)K-Akt-mTOR- and Ras-Raf-MEK-Erk1/2 signaling in NET disease.
收起
展开
DOI：
10.1016/j.canlet.2010.02.018
被引量：
年份：
1970
ResearchGate
(全网免费下载)
钛学术
(全网免费下载)
通过 文献互助 平台发起求助，成功后即可免费获取论文全文。
求助方法1：
知识发现用户
每天可免费求助50篇
求助方法1：
关注微信公众号
每天可免费求助2篇
求助方法2：
完成求助需要支付5财富值
您目前有 1000 财富值
相似文献(259)
参考文献(0)
引证文献(60)
来源期刊
影响因子：暂无数据
JCR分区： 暂无
中科院分区：暂无
